PETRI DISH PERSPECTIVES – Details, episodes & analysis

Podcast details

Technical and general information from the podcast's RSS feed.

PETRI DISH PERSPECTIVES

Manead Khin

Science

Health & Fitness

Frequency: 1 episode/7d. Total Eps: 81

Burma | Chicago
Scientist 🥼🧪🔬
Covering biotech, pharma, and healthcare companies shaping the world 🧬🏥🌎

Stream new episodes every THURSDAY!

https://linktr.ee/maneadkhin

#biotech #pharma #healthcare #podcast #petridishperspectives

Read moreCollapse

Site

RSS

Apple

Data updated on 06/09/2026

Recent rankings

Latest chart positions across Apple Podcasts and Spotify rankings.

Apple Podcasts

Spotify

No recent rankings available

Shared links between episodes and podcasts

Links found in episode descriptions and other podcasts that share them.

See all

https://www.buzzsprout.com/2437458/support
81 shares
https://www.buzzsprout.com/2437458/fan_mail/new
81 shares
https://www.buzzsprout.com/twilio/text_messages/2437458/open_sms
46 shares

RSS feed quality and score

Technical evaluation of the podcast's RSS feed quality and structure.

See all

RSS feed quality

To improve

Score global : 48%

Publication history

Monthly episode publishing history over the past years.

Year

Latest published episodes

Recent episodes with titles, durations, and descriptions.

See all

Episode 71: Fate of Pharma M&A

Season 1 · Episode 71

Thursday, September 3, 2026 • Duration 22:24

Send us Fan Mail

In this episode of Petri Dish Perspectives, we take a step back from individual companies to examine one of the most powerful forces shaping the pharmaceutical industry: M&A, licensing, and the global competition for innovation.

We explore how today's pharmaceutical giants were built through decades of consolidation, from Pfizer, GlaxoSmithKline, and Novartis to some of the industry's biggest modern transactions and why dealmaking has increasingly become essential for companies facing massive patent cliffs. But modern pharma is changing. Instead of relying solely on internal R&D or pursuing enormous megamergers, companies are increasingly acquiring targeted biotechs, licensing individual assets, and looking outside traditional innovation hubs for their next blockbuster.

We'll also dive into one of the biggest shifts happening in biotech today: the rise of China and Asia as sources of innovative drug development. Western pharmaceutical companies are increasingly licensing molecules and technologies developed outside the U.S. and Europe, even as governments push for supply-chain independence and greater scrutiny of strategic relationships with China. What happens when the pharmaceutical industry is becoming more global while geopolitics is becoming less global?

From the biggest deals in pharmaceutical history to the future of cross-border biotech partnerships, this episode asks a bigger question: Has Big Pharma become too dependent on buying innovation rather than building it? And if the best science can increasingly come from anywhere in the world, who will ultimately control the future of medicine?

Because pharmaceutical M&A isn't just about buying companies. It's about deciding who gets to own the future of medicine.

🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes!

https://linktr.ee/maneadkhin

#PetriDishPerspectives #Pharma #Biotech #PharmaMA #BiotechMA #DrugDevelopment #BigPharma #PharmaceuticalIndustry #BiotechInnovation #Healthcare #LifeSciences #BusinessDevelopment #Licensing #PatentCliff #ChinaBiotech #GlobalHealth #Geopolitics #DrugDiscovery #Innovation #HealthcareInnovation

Support the show

Read moreCollapse

August 2026: Biotech & Pharma NEWS Roundup

Tuesday, September 1, 2026 • Duration 11:29

Send us Fan Mail

Welcome to your essential overview of the global biotech and pharmaceutical landscape for August 2026!

This month was defined by major dealmaking, a resurgence in biotech financing, and growing questions about where the global biotech industry is headed. Roche made a $2.5 billion bet on Hanmi, McKesson acquired Precision Medicine Group for $2.25 billion, and the investors behind Metsera quickly returned with Sentivera and a licensing deal worth up to $1.5 billion. Meanwhile, companies including Apnimed, Attovia, and Braveheart kept the IPO market active, suggesting that investor appetite for biotech may be continuing to recover. On the regulatory front, a series of FDA approvals expanded treatment options across HIV, autoimmune disease, cardiovascular disease, cancer, and rare disorders, while three reported deaths in Chinese gene therapy trials sparked renewed debate in Washington about clinical-trial oversight and the FDA's reliance on international data. The bigger story is clear: biotech is becoming increasingly global, capital-intensive, and interconnected, where success depends not only on great science, but also on manufacturing, financing, regulation, and strategic partnerships.

🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes!

https://linktr.ee/maneadkhin

#PetriDishPerspectives #BiotechNews #PharmaNews

Support the show

Read moreCollapse

Episode 70: Cellares

Season 1 · Episode 70

Thursday, August 27, 2026 • Duration 21:43

Send us Fan Mail

In this episode of Petri Dish Perspectives, we explore Cellares, the biotech company trying to solve one of the biggest and least discussed challenges in cell therapy: how do you manufacture these complex, personalized medicines at commercial scale? From CAR-T to gene-edited cell therapies, the science may be advancing rapidly, but manufacturing remains labor-intensive, expensive, and difficult to scale. Cellares believes the answer is automation.

We’ll break down the origins of Cellares, the engineering philosophy behind its Cell Shuttle platform, and how the company is attempting to turn cell therapy manufacturing into something closer to an automated pharmaceutical factory. We’ll also explore its partnerships with companies including Bristol Myers Squibb and Cabaletta Bio, the massive investment behind its Smart Factory network, and why pharmaceutical companies have become increasingly interested in automating cell therapy production.

But there’s a major twist: Bristol Myers Squibb recently terminated its partnership with Cellares, raising questions about whether the Cell Shuttle is truly ready for commercial-scale manufacturing. We’ll unpack what happened, why manufacturing a clinical-stage therapy isn't necessarily the same as manufacturing a commercial product, and what this could mean for Cellares and the broader future of automated cell therapy.

Because the next breakthrough in cell therapy may not be another drug, it may be the factory that finally makes these living medicines scalable.

🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!

https://linktr.ee/maneadkhin

#PetriDishPerspectives #Cellares #CellTherapy #CAR_T #CAR-T #Biotech #Biotechnology #Pharma #CellTherapyManufacturing #Biomanufacturing #GeneTherapy #DrugDevelopment #LifeSciences #Healthcare #BristolMyersSquibb #CabalettaBio #CellShuttle #Manufacturing #BiotechInnovation #PrecisionMedicine

Support the show

Episode 69: Summit Therapeutics

Season 1 · Episode 69

Thursday, August 20, 2026 • Duration 21:51

Send us Fan Mail

In this episode of Petri Dish Perspectives, we explore the remarkable rise of Summit Therapeutics, a biotech that transformed itself from an infectious-disease company into one of the most closely watched oncology companies in the world. At the center of the story is ivonescimab, a next-generation bispecific antibody targeting both PD-1 and VEGF and a drug that could potentially challenge Merck’s blockbuster Keytruda.

We’ll dive into Summit’s origins, the company’s dramatic pivot, the story behind its partnership with China’s Akeso, and the science behind why combining immune checkpoint inhibition with VEGF blockade could create a powerful new approach to cancer treatment. We’ll also break down the clinical data in lung cancer, Summit’s growing pipeline, the massive commercial opportunity, and the risks surrounding regulatory approval, clinical durability, and the company’s heavy dependence on a single lead asset.

But Summit’s story goes far beyond one cancer drug. Ivonescimab represents a broader shift in how medicines are discovered and commercialized, with innovative assets increasingly emerging from Chinese biotech and being licensed by Western companies for global development. Could Summit become the company that brings a new generation of cancer therapeutics to the world and could ivonescimab really become a challenger to Keytruda?

🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!

https://linktr.ee/maneadkhin

#PetriDishPerspectives #SummitTherapeutics #Ivonescimab #Biotech #Biotechnology #Pharma #Oncology #Cancer #CancerResearch #Immunotherapy #BispecificAntibodies #PrecisionMedicine #DrugDevelopment #ClinicalTrials #Keytruda #Merck #ChineseBiotech #Healthcare #LifeSciences #PharmaceuticalIndustry

Support the show

Episode 68: Guardant Health

Season 1 · Episode 68

Thursday, August 13, 2026 • Duration 23:24

Send us Fan Mail

In this episode of Petri Dish Perspectives, we explore the story of Guardant Health, one of the companies leading the shift toward blood-based cancer detection and precision oncology. Founded by genomic scientists Helmy Eltoukhy and AmirAli Talasaz, Guardant is betting that a simple blood draw can reveal critical information about the biology of a tumor, from identifying mutations and guiding treatment to monitoring residual disease and potentially detecting cancer earlier.

We'll dive into the science behind liquid biopsy and circulating tumor DNA, Guardant's evolution from Guardant360 into a broader precision-oncology platform, the rise of its Shield colorectal cancer screening test, and the company's growing role in pharmaceutical drug development, real-world evidence, and AI. We'll also explore the promise and major challenges of multi-cancer early detection, including the questions around sensitivity, false positives, reimbursement, and whether detecting cancer earlier actually translates into better outcomes.

Because the future of cancer care may not just be about developing better treatments, but about being able to continuously read what cancer is doing inside the body from something as simple as a blood sample.

🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!

https://linktr.ee/maneadkhin

#PetriDishPerspectives #GuardantHealth #LiquidBiopsy #Cancer #Oncology #Biotech #Healthcare #PrecisionMedicine #CancerDetection #Genomics #ctDNA #Diagnostics #HealthTech #Pharma #AI #Biotechnology #FutureOfHealthcare

Support the show

Read moreCollapse

Episode 67: Epic Systems

Season 1 · Episode 67

Thursday, August 6, 2026 • Duration 23:08

Send us Fan Mail

In this episode of Petri Dish Perspectives, we explore the story of Epic Systems, the privately held healthcare technology company that has quietly built much of the digital infrastructure behind American healthcare. From Judy Faulkner founding Epic in a Wisconsin basement to becoming the dominant electronic health record platform, Epic has transformed how hospitals, physicians, and patients interact with medical information.

We'll dive into Epic's founding story, the evolution of its electronic health record, the rise of MyChart and Cosmos, and how Epic built a massive competitive moat through interoperability, data, workflow integration, and switching costs. We'll also explore its growing role in artificial intelligence, how Epic is embedding AI directly into clinical workflows, and the battle with companies like Oracle Health to control the future of healthcare data.

Because the next generation of healthcare won't just be about developing better drugs and devices, it will be about who controls the information infrastructure connecting patients, providers, data, and AI.

🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!

https://linktr.ee/maneadkhin

#PetriDishPerspectives #EpicSystems #Healthcare #HealthTech #Biotech #Pharma #AI #ArtificialIntelligence #DigitalHealth #HealthcareInnovation #JudyFaulkner #EHR #HealthData #MedTech #FutureOfHealthcare

Support the show

Read moreCollapse

July 2026: Biotech & Pharma NEWS Roundup

Saturday, August 1, 2026 • Duration 09:27

Send us Fan Mail

Welcome to your essential overview of the global biotech and pharmaceutical landscape for June 2026!

This month was dominated by AI cementing itself as a core part of drug discovery, with partnerships spanning Anthropic, NVIDIA, Insilico Medicine, and major pharmaceutical companies. At the same time, billion-dollar licensing deals and acquisitions showed that large pharma is aggressively buying innovation rather than building everything internally, particularly in obesity, oncology, radiopharmaceuticals, and gene editing. Regulatory headlines—from the FTC's lawsuit against Hims & Hers to renewed debates around animal testing—reminded us that policy is evolving just as quickly as the science. And with companies like Apnimed and Scribe Therapeutics successfully entering the public markets, investor confidence appears to be returning to biotech. The takeaway is clear: the future of healthcare will be shaped by the convergence of biology, artificial intelligence, precision medicine, and strategic dealmaking—and this month may be remembered as another major step toward that future.

🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes!

https://linktr.ee/maneadkhin

#PetriDishPerspectives #BiotechNews #PharmaNews

Support the show

Read moreCollapse

Episode 66: Scribe Therapeutics

Season 1 · Episode 66

Thursday, July 30, 2026 • Duration 23:51

Send us Fan Mail

In this episode of Petri Dish Perspectives, we explore the story of Scribe Therapeutics, one of genome editing's most ambitious companies aiming to move beyond first-generation CRISPR. Rather than accepting the size, delivery, and precision limitations of traditional Cas9, Scribe is redesigning the molecular machinery itself, building smaller, faster, and more versatile X-Editors and pioneering the future of epigenetic regulation.

We'll dive into the origins of CRISPR from bacterial immune systems to Nobel-winning breakthroughs, the protein engineering philosophy of co-founder Jennifer Doudna and Benjamin Oakes, and why pharmaceutical giants like Biogen, Eli Lilly, and Sanofi have poured resources into its platform. We'll also break down its pipeline targeting cardiometabolic diseases, rare genetic disorders, and the promise of reversible gene silencing.

Because the next era of genetic medicine won't just belong to those who discover biology, but to those who engineer it into safer, more precise cures.

🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!

https://linktr.ee/maneadkhin

#PetriDishPerspectives #ScribeTherapeutics #Biotech #CRISPR #GeneEditing #ProteinEngineering #Genomics #Genetics #DrugDevelopment #Pharma #Biotechnology #LifeSciences #Cardiometabolic #Epigenetics #Healthcare #SciencePodcast #FutureOfMedicine #PrecisionMedicine #BiotechPodcast

Support the show

Read moreCollapse

Episode 65: Apogee Therapeutics

Season 1 · Episode 65

Thursday, July 23, 2026 • Duration 23:29

Send us Fan Mail

In this episode of Petri Dish Perspectives, we explore the story of Apogee Therapeutics, one of biotech's newest immunology companies aiming to redefine autoimmune disease through next-generation antibody engineering. Rather than chasing entirely new biological targets, Apogee is focused on improving what already works, developing longer-lasting biologics that could reduce injections from every few weeks to every few months.

We'll dive into the evolution of modern immunology, the science behind cytokines and Fc engineering, how Apogee emerged from biotech incubator Paragon Therapeutics, and why investors have poured hundreds of millions of dollars into its vision. We'll also break down its pipeline, including APG777, APG808, and other promising candidates targeting eczema, asthma, inflammatory bowel disease, and beyond.

Because sometimes the biggest innovation isn't discovering new biology, it's engineering better medicines for the patients who depend on them.

🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!

https://linktr.ee/maneadkhin

#PetriDishPerspectives #ApogeeTherapeutics #Biotech #Immunology #AutoimmuneDisease #Biologics #AntibodyEngineering #DrugDevelopment #Pharma #Biotechnology #LifeSciences #Dermatology #Asthma #Inflammation #ProteinEngineering #Healthcare #SciencePodcast #FutureOfMedicine #PrecisionMedicine #BiotechPodcast

Support the show

Read moreCollapse

Episode 64: Conception Bio

Season 1 · Episode 64

Thursday, July 16, 2026 • Duration 23:16

Send us Fan Mail

In this episode of Petri Dish Perspectives, we explore the story of Conception Bio, one of the most ambitious biotechnology companies working at the intersection of stem cell biology, reproductive medicine, and regenerative science. Their mission? To make eggs from ordinary cells through in vitro gametogenesis (IVG), a breakthrough that could fundamentally change how we think about infertility, fertility preservation, and human reproduction.

We'll dive into the science behind IVG, the pioneering research that made the field possible, the founders' vision, and why investors believe reproductive biology could become one of biotech's next major frontiers. We'll also discuss the enormous technical hurdles, ethical questions, and potential applications for cancer survivors, age-related infertility, LGBTQ+ family building, and beyond.

Because the next revolution in medicine may not be about curing disease, it may be about creating life's very first cell.

🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!

https://linktr.ee/maneadkhin

#PetriDishPerspectives #ConceptionBio #Fertility #IVF #StemCells #RegenerativeMedicine #Biotech #ReproductiveBiology #InVitroGametogenesis #IVG #DrugDiscovery #Healthcare #LifeSciences #DevelopmentalBiology #PrecisionMedicine #WomenInScience #Biotechnology #SciencePodcast #FutureOfMedicine #BiotechPodcast

Support the show

Read moreCollapse

PETRI DISH PERSPECTIVES – Details, episodes & analysis

Podcast details

Recent rankings

Apple Podcasts

Spotify

Shared links between episodes and podcasts

RSS feed quality and score

Publication history

Latest published episodes

Related Shows Based on Content Similarities

Related Shows Based on Content Similarities

Apple Podcasts

Spotify

PETRI DISH PERSPECTIVES – Details, episodes & analysis

Podcast details

Recent rankings

Apple Podcasts

Spotify

Shared links between episodes and podcasts

Buzzsprout3

RSS feed quality and score

Publication history

Latest published episodes

Similar podcasts and content

Related Shows Based on Content Similarities

Related Shows Based on Content Similarities

Buzzsprout3

Apple Podcasts

Spotify